Empyrean Neuroscience
New York
About Empyrean Neuroscience
Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $22.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2022)
- Website: empyrean.bio
Industries & Categories
Biotechnology, Life Science, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/empyrean-neuroscience-54703 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.